Applied Filters
Personal Genomics takes PacBio dispute to Chinese court
Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.
Natera and Illumina settle litigation, agree mutual licence
Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Merck expands CRISPR patent portfolio
Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.
Merck KGaA secures second US CRISPR patent
Millipore Sigma, the US life sciences business of Merck KGaA, has secured a patent for its CRISPR-chrom technology, bringing its total number of CRISPR-related patents to 23.
EIP boosts life sciences practice with Mathys & Squire partner
IP law firm EIP has enhanced its life science capabilities with the addition of Monika Rai as a partner.
Webinar: Plenty to fight for in CRISPR IP battle
Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
PacBio pledges to fight invalidation of patents after bitter dispute
California-based Pacific Biosciences has accused a UK rival of exploiting the coronavirus pandemic in a patent infringement trial.
Fed Circuit restores two Illumina DNA patents in blow to Roche
The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Biogen blocking bid rejected; signs $2.4bn deal
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
University of California gains ground after EPO backs CRISPR patent
In a victory for the University of California, the European Patent Office has affirmed a CRISPR patent issued to Emmanuelle Charpentier, the University of California, and the University of Vienna.
